From: Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies
Study | Patients’ country | No. of patients | Tumor stagea | Treatment methods | Cutoff value | Specimen type |
---|---|---|---|---|---|---|
Breast cancer | ||||||
 Johansen 1995 [9] | Denmark | 41 | – | Chemotherapy | 207 μg/L | Serum |
 Jensen 2003 [21] | Denmark | 100 | Metastatic disease (100) | Chemotherapy | 168 μg/L | Serum |
 Johansen 2003 [22] | England | 271 | – | Surgery and chemotherapy and radiotherapy | – | Serum |
 Yamac 2008 [29] | Turkey | 45 | I–III (62.2) | Surgery and chemotherapy | – | Serum |
 Wang 2012 [38] | China | 120 | TNM I–III (23.3) | Surgery | – | Serum |
Gastrointestinal tumors | ||||||
 Cintin 1999 [18] | Denmark | 603 | Dukes’ staging A–D (53.4) | Surgery | 247 μg/L | Serum |
 Chang 2009 [30] | America | 52 | II–III (–) | Chemotherapy and radiotherapy | Continuous variable | Plasma |
 Zhu 2012 [39] | China | 212 | – | Chemoembolization | 106 μg/L | Serum |
 Zhu 2012 [40] | China | 158 | TNM I–IV (38.0) | Surgery | Continuous variable | Serum |
 Schultz 2013 [41] | Denmark and Germany | 103 | – | Surgery; chemotherapy (not undergoing surgery) | 116 μg/L | Plasma |
370 | ||||||
 Liu 2014 [43] | China | 86 | UICC I–IV (44.2) | Surgery and chemotherapy | 216 μg/L | Serum |
 Tarpgaard 2014 [44] | 32 Nordic centers | 510 | Metastatic disease (100) | Chemotherapy | Continuous variable | Plasma |
 Jensen 2016 [47] | Denmark | 162 | Metastatic disease (100) | Cetuximab and irinotecan | Continuous variable | Plasma |
98 | ||||||
 Thongsom 2016 [50] | Thailand | 57 | TNM I–IV (78.9) | Surgery | 100.7 μg/L | Plasma |
 Gramkow 2017 [52] | Finland | 457 | Metastatic disease (100) | Liver resection | – | Serum |
 Fuksiewicz 2018 [55] | Poland | 83 | – | Surgery | 44.6 μg/L | Serum |
Ovarian cancer | ||||||
 Dehn 2003 [19] | Denmark | 73 | I–IV (75.3) | Chemotherapy | 160 μg/L | Plasma |
 Høgdall 2003 [20] | Denmark | 47 | III(100) | Surgery | 130 μg/L | Plasma |
 Høgdall 2009 [31] | Denmark | 76 | I–IV (72.4) | Surgery and chemotherapy | – | Plasma |
 Boisen 2016 [49] | Denmark | 140 | FIGO I–IV (82.1) | Bevacizumab | – | Plasma |
Lung cancer | ||||||
 Johansen 2004 [23] | Denmark | 131 | Limited and extended disease (55.0) | Chemotherapy | – | Serum |
 Choi 2010 [34] | Korea | 39 | IIIB–IV (100) | Chemotherapy | 165 μg/L | Serum |
 Thöm 2010 [35] | Germany | 189 | III–IV (100) | Chemotherapy | 209 μg/L | Serum |
 Xu 2014 [46] | China | 120 | Limited and extended disease (41.7) | Chemotherapy | 65.7 μg/L | Serum |
 Matsuo 2019 [57] | Japan | 50 | III–IV (100) | Anti-PD-1 inhibitor | – | Plasma |
Urologic neoplasms | ||||||
 Brasso 2006 [24] | Denmark | 152 | Metastatic disease (100) | Endocrine therapy | 104 μg/L | Serum |
 Johansen 2007 [27] | Denmark | 102 | – | Total androgen ablation or parenteral estrogen | Continuous variable | Serum |
 Tschirdewahn 2014 [45] | Germany | 101 | T stage Ta–T4 (45.5) | Surgery | 90 μg/L | Serum |
 Vom Dorp 2016 [48] | Germany | 152 | Stage pT1–T4 (40.1) | Surgery | 185 μg/L | Serum |
 Väänänen 2017 [54] | Finland | 82 | Metastatic and non-metastatic disease (25.6) | Surgery | 120 μg/L | Serum |
 Darr 2018 [56] | Germany | 109 | Metastatic disease(100) | Chemotherapy | 160 μg/L | Serum |
Melanoma | ||||||
 Schmidt 2006 [25] | Denmark | 225 | I–II (0) | Surgery | 124 μg/L | Serum |
 Schmidt 2006 [26] | Denmark | 110 | IV (100) | Chemotherapy and immunotherapy | 124 μg/L | Serum |
 Krogh 2016 [51] | Europe | 299 | Stage IIB and III (–) | Untreated | Continuous variable | Serum |
 Erturk 2017 [53] | Turkey | 112 | – | chemotherapy and radiotherapy and immunotherapy | 174.88 μgL | Serum |
Squamous cell carcinoma of the head and neck | ||||||
 Roslind 2008 [28] | Denmark | 144 | I–IV (55.6) | Radiotherapy | – | Serum |
Multiple tumors | ||||||
 Johansen 2009 [32] | Denmark | 1432 | Localized disease and metastatic disease (40.8) | – | – | Plasma |
Cervical adenocarcinoma | ||||||
 Mitsuhashi 2009 [33] | Japan | 37 | I–IV (29.7) | Surgery and chemoradiation | 130 μg/L | Serum |
Glioblastoma | ||||||
 Iwamoto 2011 [36] | America | 141 | – | Surgery | 98 μg/L | Serum |
 Bernardi 2012 [37] | Italy | 60 | Astrocytoma Grade IV (100) | Surgery and irradiation and chemotherapy | – | Serum |
 Gállego 2014 [42] | France | 111 | – | Surgery | 60 μg/L | Plasma |